Inve US ▾
PTPTCT

PTC Therapeutics (PTCT) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Jul 30, 2026

Source: earnings call transcript

Executive summary

PTC Therapeutics Q2 FY26 — Record Revenue and Raised Guidance Driven by Strong Sephience Launch

PTC Therapeutics delivered a strong second quarter, driven by the continued robust global launch of Sephience, which saw significant revenue growth and broad market penetration. The company raised its full-year revenue guidance, reflecting confidence in Sephience's trajectory and the unexpected durability of the DMD franchise. Progress in the pipeline, including positive votoplam data and advancement of other clinical programs, further supports the long-term growth outlook, while a strong cash balance provides strategic flexibility.

Highlights

5

  • Achieved record total revenue of $361 million, including $239 million in product revenue, representing over 100% YoY growth.

  • Raised full-year 2026 product revenue guidance to $850 million-$950 million and total revenue guidance to $1.18 billion-$1.28 billion.

  • Sephience global revenue reached $151 million, growing 21% QoQ, with 1,647 commercial patients globally and 100% penetration in US centers of excellence.

  • Votoplam's PIVOT-HD study showed positive 24-month interim results with a 52% slowing of disease progression in the 10mg Stage 2 cohort.

  • Maintained a strong cash position of $2.23 billion as of June 30, 2026, following a successful convertible note refinancing.

Concerns

2

  • DMD franchise (Translarna and Emflaza) continues to face headwinds from generic pressure and challenges in key international markets.

  • Sephience discontinuation rate remains at approximately 20%, though management views this as impressive given early patient profiles.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 product revenue
$850M-$950M
high materiality
High
Full-year 2026 total revenue
$1.18B-$1.28B
high materiality
High
Cash flow breakeven
potentially reach
medium materiality
Medium
Sephience global commercial opportunity
$2B+
high materiality
High
International revenue contribution for Sephience
increasingly contribute
medium materiality
High
Germany Sephience pricing and reimbursement
finalized
medium materiality
High
France Sephience pricing and reimbursement
conclude sometime next year
medium materiality
Medium
Italy and Spain Sephience pricing and reimbursement
conclude sometime in early 2027
medium materiality
Medium

Segment performance

SegmentRevenueYoYQoQMargin
Sephience
Strong global launch momentum with increasing contributions internationally, exceeding internal expectations in Japan. Broad uptake across patient segments and age groups worldwide.
Commercial patients globally: 1,647 (as of June 30, 2026)US Centers of Excellence penetration: 100%
$151M—21%—
DMD franchise
Continued sales despite challenges from generic pressure for Emflaza and headwinds in some larger countries for Translarna.
$67M———
Translarna
Includes a government purchase order from Russia, with continued sales in Europe and Latin America.
$42M———
Emflaza
Continues to see new prescriptions and ongoing brand loyalty despite generic pressure.
$25M———
Evrysdi
Royalty revenue generated from Roche's global sales of Evrysdi.
Royalty revenue: $71MRoche global revenue: ~$628M
————

PTCT operating KPIs by quarter

PTCT operating KPIs stated on its earnings calls, by fiscal quarter
KPI Mar 2026 Q1 FY26This call Jun 2026 Q2 FY26Change vs prior quarter
Patients Commercial
1,244 As of March 31, we had 1,244 commercial patients globally. Source: earnings call transcript
1,647 And as of June 30, we had 1,647 commercial patients on Sephience globally. Source: earnings call transcript
+32.4%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Deals & partnerships

Novartis Collaboration on votoplam Huntington's disease program

Novartis initiated enrollment in the global Phase III INVEST-HD study, which is being conducted and funded by Novartis. Novartis and PTC teams are finalizing a plan to engage with FDA in H2 2026 to discuss 24-month results and potential accelerated path.

Risks & headwinds

DMD franchise generic pressure ongoing

significant number of generics now for Emflaza

Mitigation:ongoing brand loyalty attributable in part to our programs and continued high-touch white glove services from our PTC Cares team

DMD franchise international headwinds ongoing

headwinds in some of the larger countries where we get group purchase orders

Mitigation:continued sales in Europe and Latin America as well as the government order from Russia

Translarna selling in Europe without a license ongoing

not quantified

Mitigation:continued sales in Europe and Latin America

What to watch in Q3 FY26

Votoplam FDA discussion on accelerated path

H2 2026
Current PTC and Novartis finalizing plan to engage FDA in H2 2026.
Target FDA's receptiveness to accelerated path based on 24-month PIVOT-HD data.

Why it matters

Could significantly accelerate market access for a disease-modifying therapy for Huntington's disease.

the Novartis and PTC teams are finalizing a plan to engage with FDA in the second half of 2026 to discuss the 24-month results and potential accelerated path.

Find out whether PTCT delivers this. Inve re-checks your case every morning.

Q&A highlights

What is the estimated US patient penetration for Sephience (around 10% of 17,000 population)? What percentage of patients might try the therapy? What are the key goals for upcoming medical conferences?

The company is excited about early demand but acknowledges a long way to go, with 100% penetration into US centers of excellence. They estimate about 70% of individuals tried Kuvan, suggesting a large untapped population. Conference goals include promoting awareness, demonstrating benefits for classical PKU and BH4 non-responsive patients, and reinforcing data for switches from generic therapies.

“I think when we look to metrics thus far and we see penetration into 100% of the centers of excellence, that's really an incredible milestone this early, and it basically puts us in the position we want to be with a strong base of patients to now go deeper and deeper into those centers.”

asked by Kristen Kluska · answered by Matthew Klein

2 min read 7 chapters

Detailed narrative

Sephience Global Launch Momentum

PTC Therapeutics reported record Sephience global revenue of $151 million, a 21% sequential increase, with 1,647 commercial patients globally as of June 30, 2026. The US market achieved 100% penetration of centers of excellence, with broad uptake across all patient segments and age groups. International momentum is building, with strong early uptake in Japan and accelerated demand in European early access programs, reinforcing confidence in the $2 billion-plus global opportunity.

Votoplam Huntington's Disease Program

Positive 24-month interim analysis results from the PIVOT-HD study demonstrated dose-dependent slowing of disease progression on cUHDRS, including an average 52% slowing relative to natural history in the 10mg Stage 2 cohort, with a favorable safety profile. Novartis has initiated enrollment in the global Phase III INVEST-HD study, and discussions with the FDA are planned for H2 2026 to explore a potential accelerated approval path.

Vatiquinone Friedreich's Ataxia Program

The company finalized the study protocol for PROVE-FA, an open-label trial with a natural history comparator arm, to support NDA resubmission for vatiquinone. The study, enrolling approximately 120 individuals aged 7-21 with a primary endpoint of mFARS change at month 24, is expected to initiate in Q3 FY26, reflecting key learnings from prior development.

Advancing Clinical Pipeline Programs

PTC initiated a Phase I study for PTC612, an oral NLRP3 inhibitor, with early PK/PD data expected by year-end or early next year, focusing on rare pulmonary disorders. A Phase IIa study for PTC844, a next-generation DHODH inhibitor, is planned for Q3 FY26 to assess biomarker effects in rheumatoid arthritis patients and inform future indications.

MSH3 Splicing Program (PTC303)

A development candidate, PTC303, was selected for the MSH3 splicing program, targeting triplet repeat expansion diseases like Huntington's and myotonic dystrophy. This fully owned asset is expected to enter the clinic in 2027, offering a complementary approach to HTT lowering and reinforcing PTC's leadership in small molecule splicing therapies.

Financial Strength and Capital Management

PTC closed the quarter with a strong cash, cash equivalents, and marketable securities balance of $2.23 billion, up from $1.95 billion at year-end 2025. This was supported by the strategic refinancing of the majority of 2026 convertible notes into new 2031 notes with a 0% coupon and 40% conversion premium, providing flexibility for future growth and supporting the goal of cash flow breakeven in 2026.

International Market Expansion for Sephience

Beyond the US, Sephience is gaining significant traction in international markets. Japan's early launch results exceeded expectations with rapid uptake and pricing on par with the US, locked in for 10 years. Early access programs in France, Italy, and Spain are showing accelerated demand, with pricing and reimbursement discussions ongoing, expected to conclude in late 2026 or early 2027 for these markets.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.